Antibiotics disrupt gut flora in infants: Recovery still incomplete after 8 weeks

Eight weeks after antibiotic treatment of infants, the diversity of gastrointestinal flora remained diminished, although the number of individual bacteria was back to normal, according to a paper in the November 2012 issue of the journal Antimicrobial Agents and Chemotherapy. Additionally, the potentially disease-causing Proteobacteria were now the dominant population in the treated infants.

"This is the first sequencing-based study to demonstrate the negative effects of short-term antibiotic treatment on the beneficial populations in infants," says coauthor Catherine Stanton of the Teagasc Food Research Centre, Fermoy, Cork, Ireland.

In the study, nine infants were treated with intravenous ampicillin/gentamicin within 48 hours of birth, and over the two month study period, their gastrointestinal flora were compared to that in nine control infants. At four weeks, bacteria from the beneficial genera, the Bifidobacteria and the Lactobacilli, were significantly reduced, and although the numbers bounced back by the study's end, the did not. The researchers used advanced DNA sequencing to identify the species of , and to quantify their numbers, says Stanton.

By altering the gut microbiota, and thus the immune system very early in life, the antibiotics could negatively influence long-term health, particularly by boosting the risk of developing asthma, allergy, and obesity, according to the report. The risk is heightened by the fact that the antibiotic-driven disruption of the comes at a time "when this population is in rapid flux and can easily be unbalanced," according to the report.

These results notwithstanding, because the sequencing data reveal only proportions of species present, rather than absolute numbers, it remains unclear whether the potentially harmful predominate because their population has grown or because the other populations have shrunk, the researchers write. However, the data suggest the former, which jibes with previous research.

"This research suggests that the merits of administering broad spectrum antibiotics—those that kill many bacterial species—in infants should be reassessed, to examine the potential to use more targeted, narrow-spectrum antibiotics, for the shortest period possible," says Stanton.

More information: F. Fouhy, C.M. Guinane, S. Hussey, R. Wall, C.A. Ryan, E.M. Dempsey, B. Murphy, R.P. Ross, G.F. Fitzgerald, C. Stanton, and P.D. Cotter, 2012. High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin. Antim. Agents Chemother. 56:5811-5820.

add to favorites email to friend print save as pdf

Related Stories

Resistant gut bacteria will not go away by themselves

Jun 19, 2007

E. coli bacteria that have developed resistance to antibiotics will probably still be around even if we stop using antibiotics, as these strains have the same good chance as other bacteria of continuing to colonise the gut, ...

Antibiotics have long-term impacts on gut flora

Nov 01, 2010

Short courses of antibiotics can leave normal gut bacteria harbouring antibiotic resistance genes for up to two years after treatment, say scientists writing in the latest issue of Microbiology, published on 3 November.

Gut flora affects maturation of B cells in infants

May 07, 2012

Infants whose gut is colonised by E. coli bacteria early in life have a higher number of memory B cells in their blood, reveals a study of infants carried out at the Sahlgrenska Academy at the University of Gothenburg, Sweden ...

Recommended for you

New system targets germs in donated blood plasma

14 hours ago

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

Judge halts Alzheimer's drug swap until July

Dec 16, 2014

A federal judge has ordered an Irish drug manufacturer to halt its plans to discontinue its widely used Alzheimer's medication, allegedly in an effort to drive patients to a newer patented drug.

India court blocks Bayer generic drug appeal

Dec 13, 2014

An Indian court has rejected German drug giant Bayer's bid to block a generic version of its blockbuster cancer treatment Nexavar by a local drugmaker, a move hailed by activists on Saturday.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.